Evidence map›Paper›PMID 42426342›Full record

ArticleThe EMBO journal2026

Alterations in chromatin organization promote totipotent-like features in a DPPA2/DUX-dependent manner.

Grace I Carey, Maria Vega-Sendino, Desiree Tillo, Sarah C Hoelscher, Amir Khan, Ian Taukulis, Teresa Olbrich, Bechara Saykali, Andy D Tran, Bhavya Soni and 9 more

Abstract read
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Grace I Carey *Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3498-3223
Maria Vega-Sendino *Laboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Desiree TilloCCR Genomics Core, CCR, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3568-6148
Sarah C HoelscherLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Amir KhanLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Ian TaukulisSingle Cell Analysis Facility, NCI, NIH, Bethesda, MD, USA.
Teresa OlbrichLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Bechara SaykaliLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.
Andy D TranLaboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2388-7121
Bhavya SoniLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0009-0004-9026-6941
Anna Lee FongSingle Cell Analysis Facility, NCI, NIH, Bethesda, MD, USA.
Melissa MikolajCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-5452-1683
Adam HarnedCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Kedar NarayanCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-7982-6494
Michael J KruhlakLaboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3976-6233
Michael KellySingle Cell Analysis Facility, NCI, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0654-2778
Ning Qing LiuDepartment of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-3151-638X
Elzo de WitOncode Institute and Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2883-1415
Sergio RuizLaboratory of Genome Integrity, CCR, NCI, NIH, Bethesda, MD, USA. sergio.ruizmacias@nih.gov.ORCID http://orcid.org/0000-0002-0177-6965

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Frederick National Laboratory for Cancer Research (FNLCR) 75N91019D0024NIH HHS 75N91019D00024
6 · The paper itself

Abstract

2-cell like cells (2CLC) are a transiently cycling population of cells with totipotent-associated features. Although CTCF depletion induces 2CLC conversion in mouse ESC, whether this reprogramming is a consequence of disrupted higher-order chromatin organization or of CTCF-specific functions remained unclear. Here, we show that depletion of the cohesin release factor WAPL in ESC also promotes 2CLC reprogramming, which is increased by CTCF co-depletion. Single-cell RNA-seq/ATAC-seq analyses in CTCF/WAPL-depleted ESC revealed that chromatin accessibility precedes 2C-associated gene expression. Moreover, we identified ARID3A as a transcription factor that regulates the extent of 2CLC conversion following WAPL/CTCF depletion. Although WAPL or CTCF depletion induces distinct transcriptional changes in human ESC, these do not resemble transcriptional programs of early human embryogenesis, suggesting limited evolutionary conservation. Finally, we demonstrate that 2CLC conversion mediated by alterations in chromatin organization depends on the DPPA2/DUX axis and correlates with nucleolar integrity. Together, these findings establish a mechanistic link between higher-order chromatin organization and totipotency-like cell identity in mice.

Indexed as

ChromatinHomeodomain ProteinsNuclear ProteinsAnimalsCCCTC-Binding FactorDNA-Binding ProteinsHumansMiceTranscription FactorsCCCTC-Binding FactorChromatinCtcf protein, mouseDNA-Binding ProteinsHomeodomain ProteinsNuclear ProteinsTranscription Factors

Identifiers

PMID42426342
PMCPMC13484482

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.